17:02 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $500M-$510M, consensus $506.3M
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- MIRM Upcoming Earnings Report: What to Expect?
- Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study
- Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching
- Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus
- Mirum Pharmaceuticals’ LEAP-US Study: A Long-Term Look at Livmarli’s Impact